Srinivasa Nagalla

Dr. Nagalla is the principal founder and chief executive officer of Diabetomics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of Pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums on biotechnology, genomics, and proteomics. Dr. Nagalla has over 25 years of broad, multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his MD from the All-India Institute of Medical Sciences in New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.